Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Receivables - Other: 2017-2024

Historic Receivables - Other for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $165.0 million.

  • Protagonist Therapeutics' Receivables - Other was N/A to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year change of. This contributed to the annual value of $165.0 million for FY2024, which is 64353.12% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Receivables - Other stood at $165.0 million for FY2024, which was up 64,353.12% from $256,000 recorded in FY2023.
  • Over the past 5 years, Protagonist Therapeutics' Receivables - Other peaked at $165.0 million during FY2024, and registered a low of $42,000 during FY2022.
  • In the last 3 years, Protagonist Therapeutics' Receivables - Other had a median value of $256,000 in 2023 and averaged $55.1 million.
  • Per our database at Business Quant, Protagonist Therapeutics' Receivables - Other slumped by 97.32% in 2022 and then spiked by 64,353.12% in 2024.
  • Protagonist Therapeutics' Receivables - Other (Yearly) stood at $2.4 million in 2020, then crashed by 35.45% to $1.6 million in 2021, then crashed by 97.32% to $42,000 in 2022, then spiked by 509.52% to $256,000 in 2023, then spiked by 64,353.12% to $165.0 million in 2024.